Q3 EPS Forecast for Bausch Health Cos Increased by Analyst

Key Points

• Zacks Research increased its Q3 2025 EPS forecast for Bausch Health Cos to $1.09, up from the previous estimate of $1.06, while the full-year estimate stands at $4.41 per share.
• Several analysts have upgraded Bausch Health Cos, including Wall Street Zen, which raised its rating from "hold" to "buy," and Royal Bank of Canada, which increased its target price from $8.50 to $10.00.
• Insider John Paulson significantly boosted his stake in the company, acquiring over 34 million shares at an average price of $9.00, indicating strong confidence in the company's future potential.

Bausch Health Cos Inc. (NYSE:BHC - Free Report) - Equities research analysts at Zacks Research boosted their Q3 2025 earnings estimates for Bausch Health Cos in a research report issued on Wednesday, August 20th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $1.09 for the quarter, up from their previous estimate of $1.06. The consensus estimate for Bausch Health Cos' current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos' FY2025 earnings at $3.77 EPS, Q1 2026 earnings at $0.87 EPS, Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.13 EPS, Q1 2027 earnings at $1.03 EPS, Q2 2027 earnings at $1.03 EPS and FY2027 earnings at $4.61 EPS.

Several other brokerages have also weighed in on BHC. Wall Street Zen raised shares of Bausch Health Cos from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Royal Bank Of Canada increased their target price on shares of Bausch Health Cos from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Three research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $9.00.

Bausch Health Cos Price Performance

Bausch Health Cos stock opened at $7.4950 on Friday. Bausch Health Cos has a 12-month low of $4.25 and a 12-month high of $9.85. The stock has a market cap of $2.77 billion, a P/E ratio of 28.83 and a beta of 0.41. The company has a 50-day moving average price of $6.58 and a 200 day moving average price of $6.04. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 141.90.

Bausch Health Cos (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.07). Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%.The firm had revenue of $2.57 billion for the quarter, compared to analyst estimates of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS.

Insider Activity at Bausch Health Cos

In other Bausch Health Cos news, Director John Paulson acquired 34,721,118 shares of the stock in a transaction dated Thursday, August 14th. The stock was acquired at an average price of $9.00 per share, with a total value of $312,490,062.00. Following the completion of the purchase, the director owned 70,755,869 shares in the company, valued at $636,802,821. This trade represents a 96.35% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have purchased a total of 44,316,834 shares of company stock valued at $369,628,560 over the last ninety days. Company insiders own 8.05% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. SBI Securities Co. Ltd. boosted its stake in shares of Bausch Health Cos by 244.2% in the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock valued at $27,000 after purchasing an additional 3,001 shares during the period. Cary Street Partners Financial LLC purchased a new position in shares of Bausch Health Cos in the first quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Bausch Health Cos in the first quarter valued at approximately $27,000. Russell Investments Group Ltd. boosted its stake in shares of Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company's stock valued at $51,000 after purchasing an additional 3,106 shares during the period. Finally, Wealthquest Corp purchased a new position in shares of Bausch Health Cos in the first quarter valued at approximately $58,000. Hedge funds and other institutional investors own 78.65% of the company's stock.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.